Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712671 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
Hard Copy  Add to Basket
CD ROM  Add to Basket
Electronic (PDF)  Add to Basket
Enterprisewide  Add to Basket



Market of Paclitaxel Injection in China

CCM International Limited, July 2010, Pages: 51


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005-2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. What they effect the paclitaxel injection industry? On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the forbidden for the develop of natural yew and the development for planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price and get less profit. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How the paclitaxel APIs and paclitaxel injection manufactures replied for this change? In 2009, Sichuan Jiufeng Pharmaceutical Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.

Chinese paclitaxel injection industry has witnessed significant development from 2005-2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?

For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?

What’s more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?

Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China’s paclitaxel injection? The authors have carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.

In this report, you can obtain info about:

- Production distribution of paclitaxel APIs
- General situation of paclitaxel injection production and its manufacturers
- Top 2 pharmaceutical distribution companies in China
- Medicine bidding and purchasing platforms
- Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis
- Consumption situation of paclitaxel injection
- Government policy for paclitaxel injection and quality standards of paclitaxel injection
- circulation model of paclitaxel injection in China

With the information covered in the report, readers can see the general production and consumption situation, circulation model, as well as APIs supply situation for China paclitaxel injection manufacturers in China, which are beneficial for the investors’ decision making.



Customers who bought this item also bought

Human Reproductive Technologies - Global Strategic Business Report

Injectable Generic Drugs: Prospects & Opportunities to 2013

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

Monoclonal Antibody Based Products - Global Strategic Business Report

Molecular Diagnostics Survey 2009: A Report on the Status of the U.S. Market

The Hospital Market for Standard IV Administration Sets in France

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

Molecular Diagnostics in Cancer Testing

Corrosion Inhibitors - Global Strategic Business Report

Chinese Markets for Medical Plastics



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds